Stress Ulcer Prophylaxis Versus Placebo-A Blinded Pilot Randomized Controlled Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease

• Published in: Pediatric critical care medicine Vol. 25; no. 2; p. 118
• Main Authors: Mills, Kimberly I, Albert, Ben D, Bechard, Lori J, Chu, Stephen, Duggan, Christopher P, Kaza, Aditya, Rakoff-Nahoum, Seth, Sleeper, Lynn A, Newburger, Jane W, Priebe, Gregory P, Mehta, Nilesh M
• Format: Journal Article
• Language: English
• Published: United States 01.02.2024
• Subjects: Critical Illness - therapy; Gastrointestinal Hemorrhage - prevention & control; Heart Defects, Congenital - complications; Humans; Infant; Peptic Ulcer - prevention & control; Pilot Projects; Treatment Outcome; Ulcer - complications
• ISSN: 1529-7535; 1947-3893
• DOI: 10.1097/PCC.0000000000003384

The routine use of stress ulcer prophylaxis (SUP) in infants with congenital heart disease (CHD) in the cardiac ICU (CICU) is controversial. We aimed to conduct a pilot study to explore the feasibility of performing a subsequent larger trial to assess the safety and efficacy of withholding SUP in this population (NCT03667703). Single-center, prospective, double-blinded, parallel group (SUP vs. placebo), pilot randomized controlled pilot trial (RCT) in infants with CHD admitted to the CICU and anticipated to require respiratory support for greater than 24 hours. Patients were randomized 1:1 (stratified by age and admission type) to receive a histamine-2 receptor antagonist or placebo until respiratory support was discontinued, up to 14 days, or transfer from the CICU, if earlier. Feasibility was defined a priori by thresholds of screening rate, consent rate, timely drug allocation, and protocol adherence. The safety outcome was the rate of clinically significant upper gastrointestinal (UGI) bleeding. We screened 1,426 patients from February 2019 to March 2022; of 132 eligible patients, we gained informed consent in 70 (53%). Two patients did not require CICU admission after obtaining consent, and the remaining 68 patients were randomized to SUP (n = 34) or placebo (n = 34). Ten patients were withdrawn early, because of a change in eligibility (n = 3) or open-label SUP use (n = 7, 10%). Study procedures were completed in 58 patients (89% protocol adherence). All feasibility criteria were met. There were no clinically significant episodes of UGI bleeding during the pilot RCT. The percentage of patients with other nonserious adverse events did not differ between groups. Withholding of SUP in infants with CHD admitted to the CICU was feasible. A larger multicenter RCT designed to confirm the safety of this intervention and its impact on incidence of UGI bleeding, gastrointestinal microbiome, and other clinical outcomes is warranted.